Key Takeaway: CG Oncology has announced positive initial results from the CORE-008 trial, which assesses an intravesical combination therapy for patients who are high-risk and have been exposed to or are unresponsive to BCG treatment. This development highlights the company's commitment to addressing unmet needs in bladder cancer treatment.
Price reaction · baseline $43.21 (2025-10-29T15:19:00.000Z) · hit during market hours · 3 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-0.5%
Market Sentiment Analysis
POSITIVE FACTORS
CG Oncology reports positive results from CORE-008 trial.
The trial evaluates a promising intravesical combination therapy.
Focus on high-risk BCG-exposed and unresponsive patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer
Full Press Release Details
by admin | Oct 29, 2025 | congress-hub-posters
Recent Posts
• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation
Recent Comments
Frequently Asked Questions
What is the CORE-008 trial about?
The CORE-008 trial evaluates an intravesical combination therapy for bladder cancer.
Who are the patients targeted in the CORE-008 trial?
The trial focuses on high-risk patients who are BCG-exposed or unresponsive.
What were the results of the CORE-008 trial?
CG Oncology reported positive initial results from the CORE-008 trial.